Balloon angioplasty versus stenting with nitinol stents in the superficial femoral artery

ISRCTN ISRCTN52947529
DOI https://doi.org/10.1186/ISRCTN52947529
ClinicalTrials.gov number NCT00281060
Secondary identifying numbers EK 164/2003
Submission date
23/01/2006
Registration date
26/05/2006
Last edited
14/10/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Martin Schillinger
Scientific

Medical University Vienna
General Hospital Department of Internal Medicine II, Angiology
Waehringer Guertel 18-20
Vienna
A 1090
Austria

Email martin.schillinger@meduniwien.ac.at

Study information

Study design1:1 randomized controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study acronymAbsolute Trial
Study objectivesPrimary stenting with self-expanding nitinol stents may improve patency after endovascular treatment of superficial femoral artery obstructions compared to balloon angioplasty with optional stenting
Ethics approval(s)Approved by the Ethics Committee of the Medical University of Vienna and Vienna General Hospital, reference number: EK 164/2003
Health condition(s) or problem(s) studiedPeripheral artery disease, superficial femoral artery stenosis or occlusion
InterventionGroup 1: primary stenting
Group 2: Percutaneous transluminal angioplasty (PTA) (balloon angioplasty) with optional secondary stenting
Intervention typeOther
Primary outcome measureAngiographic restenosis at six months
Secondary outcome measures1. Restenosis by duplex ultrasound at 3, 6 and 12 months
2. Walking distance on the treadmill at 3, 6 and 12 months
3. Ankle brachial index at 3, 6 and 12 months
4. Stent fractures at 6 and 12 months
Overall study start date01/06/2003
Completion date31/07/2005

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants110 patients planned
Key inclusion criteria1. Symptomatic peripheral artery disease - Rutherford stages 3 to 5
2. >50% Stenosis of the ipsilateral superficial femoral artery
3. Lesion length >30 mm
4. At least one patent crural runoff vessel
Key exclusion criteria1. Acute critical limb ischemia
2. Previous ipsilateral bypass surgery or ipsilateral superficial femoral artery (SFA) stenting
3. Untreated inflow disease
4. Known intolerance to clopidogrel, aspirin or radiocontrast
Date of first enrolment01/06/2003
Date of final enrolment31/07/2005

Locations

Countries of recruitment

  • Austria

Study participating centre

Medical University Vienna
Vienna
A 1090
Austria

Sponsor information

Medical University Vienna (Austria)
University/education

c/o Prof Erich Minar
Waehringer Guertel 18-20
Vienna
A 1090
Austria

Phone +43 (0)1 40400 4670
Email martin.schillinger@meduniwien.ac.at
ROR logo "ROR" https://ror.org/05n3x4p02

Funders

Funder type

University/education

The trial was funded by the Medical University of Vienna and Vienna General Hospital (Austria)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 04/05/2006 Yes No